Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Regenerate: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.

Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Yo Unossi Z.

Contemp Clin Trials. 2019 Jun 28. pii: S1551-7144(19)30128-4. doi: 10.1016/j.cct.2019.06.017. [Epub ahead of print]

2.

Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.

Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL.

Curr Med Res Opin. 2019 Mar;35(3):461-472. doi: 10.1080/03007995.2018.1533456. Epub 2018 Nov 22.

PMID:
30293448
3.

Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.

Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ.

Liver Int. 2019 May;39(5):924-932. doi: 10.1111/liv.13974. Epub 2019 Feb 21.

PMID:
30253043
4.

Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.

Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, McCullough AJ, Shringarpure R, Ferguson B, Lee L, Chen J, Liberman A, Shapiro D, Neuschwander-Tetri BA.

Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.

PMID:
30222962
5.

Avian scavengers and the threat from veterinary pharmaceuticals.

Cuthbert RJ, Taggart MA, Prakash V, Chakraborty SS, Deori P, Galligan T, Kulkarni M, Ranade S, Saini M, Sharma AK, Shringarpure R, Green RE.

Philos Trans R Soc Lond B Biol Sci. 2014 Nov 19;369(1656). pii: 20130574. doi: 10.1098/rstb.2013.0574.

6.

Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.

DuPont HL, Petersen A, Zhao J, Mundt A, Jiang ZD, Miller S, Flores J, Shringarpure R, Moro L, Bagin RG, Ballard ED, Totoritis MC.

J Travel Med. 2014 Nov-Dec;21(6):369-76. doi: 10.1111/jtm.12168.

7.

A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads.

Jones MP, Chey WD, Singh S, Gong H, Shringarpure R, Hoe N, Chuang E, Talley NJ.

Aliment Pharmacol Ther. 2014 Feb;39(4):426-37. doi: 10.1111/apt.12608. Epub 2014 Jan 6.

8.

A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.

Tong K, Nicandro JP, Shringarpure R, Chuang E, Chang L.

Therap Adv Gastroenterol. 2013 Sep;6(5):344-57. doi: 10.1177/1756283X13491798.

9.

Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay.

Wang SL, Hauenstein S, Ohrmund L, Shringarpure R, Salbato J, Reddy R, McCowen K, Shah S, Lockton S, Chuang E, Singh S.

J Pharm Biomed Anal. 2013 May 5;78-79:39-44. doi: 10.1016/j.jpba.2013.01.031. Epub 2013 Feb 1.

10.

The population decline of Gyps vultures in India and Nepal has slowed since veterinary use of diclofenac was banned.

Prakash V, Bishwakarma MC, Chaudhary A, Cuthbert R, Dave R, Kulkarni M, Kumar S, Paudel K, Ranade S, Shringarpure R, Green RE.

PLoS One. 2012;7(11):e49118. doi: 10.1371/journal.pone.0049118. Epub 2012 Nov 7.

11.

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A.

Aliment Pharmacol Ther. 2012 Sep;36(5):437-48. doi: 10.1111/j.1365-2036.2012.05208.x. Epub 2012 Jul 10.

12.

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE, Weyer C.

Obesity (Silver Spring). 2009 Sep;17(9):1736-43. doi: 10.1038/oby.2009.184. Epub 2009 Jun 11.

13.

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.

Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, Podar K, Catley L, Hideshima T, Chauhan D, Caulder E, Neilan CL, Vaddi K, Li J, Gramatzki M, Fridman JS, Anderson KC.

Mol Cancer Ther. 2009 Jan;8(1):26-35. doi: 10.1158/1535-7163.MCT-08-0149.

14.

Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.

Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC.

Br J Haematol. 2006 Jul;134(2):145-56.

PMID:
16846475
16.

Antimyeloma activity of heat shock protein-90 inhibition.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC.

Blood. 2006 Feb 1;107(3):1092-100. Epub 2005 Oct 18.

17.

Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.

Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM.

Cancer Res. 2005 Sep 1;65(17):7896-901.

18.

Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome.

Powell SR, Wang P, Katzeff H, Shringarpure R, Teoh C, Khaliulin I, Das DK, Davies KJ, Schwalb H.

Antioxid Redox Signal. 2005 May-Jun;7(5-6):538-46.

PMID:
15889999
19.

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

Catley L, Tai YT, Shringarpure R, Burger R, Son MT, Podar K, Tassone P, Chauhan D, Hideshima T, Denis L, Richardson P, Munshi NC, Anderson KC.

Cancer Res. 2004 Dec 1;64(23):8746-53.

20.

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.

Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K, Richardson PG, Hideshima T, Chauhan D, Anderson KC.

Cancer Res. 2004 Oct 15;64(20):7500-6.

21.

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.

Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, Hylander-Gans LL, Carrasco DR, Hideshima T, Shringarpure R, Shi J, Allam CK, Wijdenes J, Venuta S, Munshi NC, Anderson KC.

Blood. 2004 Dec 1;104(12):3688-96. Epub 2004 Aug 3.

22.

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.

Chauhan D, Li G, Hideshima T, Podar K, Shringarpure R, Mitsiades C, Munshi N, Yew PR, Anderson KC.

Oncogene. 2004 Apr 29;23(20):3597-602.

PMID:
15094775
23.

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.

Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC.

Blood. 2004 Apr 15;103(8):3158-66. Epub 2003 Dec 11.

24.

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL.

Cancer Cell. 2004 Mar;5(3):221-30.

25.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC.

Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5. Epub 2003 Dec 26.

26.

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.

Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, Burger R, Schlossman RL, Richardson PG, Pandite LN, Kumar R, Hideshima T, Chauhan D, Anderson KC.

Blood. 2004 May 1;103(9):3474-9. Epub 2003 Nov 26.

27.

Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.

Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC.

Br J Haematol. 2003 Dec;123(5):869-78.

PMID:
14632778
28.

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.

Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC.

Cancer Res. 2003 Oct 1;63(19):6174-7.

29.

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC.

Cancer Res. 2003 Sep 15;63(18):5850-8. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

30.

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.

LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC.

Blood. 2004 Mar 1;103(5):1787-90. Epub 2003 Sep 25.

31.

Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.

Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, Burger R, Munshi N, Ohtake Y, Saxena S, Anderson KC.

Blood. 2003 Nov 1;102(9):3379-86. Epub 2003 Jul 10.

32.

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC.

Blood. 2003 Oct 1;102(7):2615-22. Epub 2003 Jun 19.

33.

Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome.

Shringarpure R, Grune T, Mehlhase J, Davies KJ.

J Biol Chem. 2003 Jan 3;278(1):311-8. Epub 2002 Oct 24.

34.

Ezrin turnover and cell shape changes catalyzed by proteasome in oxidatively stressed cells.

Grune T, Reinheckel T, North JA, Li R, Bescos PB, Shringarpure R, Davies KJ.

FASEB J. 2002 Oct;16(12):1602-10.

PMID:
12374783
35.

Protein turnover by the proteasome in aging and disease.

Shringarpure R, Davies KJ.

Free Radic Biol Med. 2002 Jun 1;32(11):1084-9. Review.

PMID:
12031893
36.

Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells.

Shringarpure R, Grune T, Davies KJ.

Cell Mol Life Sci. 2001 Sep;58(10):1442-50. Review.

PMID:
11693525
37.

Age-related changes in protein oxidation and proteolysis in mammalian cells.

Grune T, Shringarpure R, Sitte N, Davies K.

J Gerontol A Biol Sci Med Sci. 2001 Nov;56(11):B459-67. Review.

PMID:
11682566
38.

Glutathiolation of the proteasome is enhanced by proteolytic inhibitors.

Demasi M, Shringarpure R, Davies KJ.

Arch Biochem Biophys. 2001 May 15;389(2):254-63.

PMID:
11339815
39.

4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease.

Shringarpure R, Grune T, Sitte N, Davies KJ.

Cell Mol Life Sci. 2000 Nov;57(12):1802-9.

PMID:
11130184

Supplemental Content

Loading ...
Support Center